These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22806212)

  • 1. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.
    Boada R; Hutaff-Lee C; Schrader A; Weitzenkamp D; Benke TA; Goldson EJ; Costa AC
    Transl Psychiatry; 2012 Jul; 2(7):e141. PubMed ID: 22806212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial.
    Costa ACS; Brandão AC; Boada R; Barrionuevo VL; Taylor HG; Roth E; Stasko MR; Johnson MW; Assir FF; Roberto MP; Salmona P; Abreu-Silveira G; Bederman I; Prendergast E; Hüls A; Abrishamcar S; Mustacchi Z; Scheidemantel T; Roizen NJ; Ruedrich S
    Lancet Neurol; 2022 Jan; 21(1):31-41. PubMed ID: 34942135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome.
    Costa AC
    Dev Neurosci; 2011; 33(5):414-27. PubMed ID: 21893967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test.
    Costa AC; Scott-McKean JJ; Stasko MR
    Neuropsychopharmacology; 2008 Jun; 33(7):1624-32. PubMed ID: 17700645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does memantine improve memory in subjects with focal-onset epilepsy and memory dysfunction? A randomized, double-blind, placebo-controlled trial.
    Leeman-Markowski BA; Meador KJ; Moo LR; Cole AJ; Hoch DB; Garcia E; Schachter SC
    Epilepsy Behav; 2018 Nov; 88():315-324. PubMed ID: 30449328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.
    Lockrow J; Boger H; Bimonte-Nelson H; Granholm AC
    Behav Brain Res; 2011 Aug; 221(2):610-22. PubMed ID: 20363261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GABA
    Block A; Ahmed MM; Rueda N; Hernandez MC; Martinez-Cué C; Gardiner KJ
    Neuroscience; 2018 Feb; 372():192-212. PubMed ID: 29292072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome.
    Ahmed MM; Dhanasekaran AR; Block A; Tong S; Costa AC; Stasko M; Gardiner KJ
    PLoS One; 2015; 10(3):e0119491. PubMed ID: 25793384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
    Peyro Saint Paul L; Creveuil C; Heinzlef O; De Seze J; Vermersch P; Castelnovo G; Cabre P; Debouverie M; Brochet B; Dupuy B; Lebiez P; Sartori É; Clavelou P; Brassat D; Lebrun-Frenay C; Daplaud D; Pelletier J; Coman I; Hautecoeur P; Tourbah A; Defer G
    J Neurol Sci; 2016 Apr; 363():69-76. PubMed ID: 27000224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
    Bakchine S; Loft H
    J Alzheimers Dis; 2007 Jul; 11(4):471-9. PubMed ID: 17656827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memantine for fragile X-associated tremor/ataxia syndrome: a randomized, double-blind, placebo-controlled trial.
    Seritan AL; Nguyen DV; Mu Y; Tassone F; Bourgeois JA; Schneider A; Cogswell JB; Cook KR; Leehey MA; Grigsby J; Olichney JM; Adams PE; Legg W; Zhang L; Hagerman PJ; Hagerman RJ
    J Clin Psychiatry; 2014 Mar; 75(3):264-71. PubMed ID: 24345444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
    Bakchine S; Loft H
    J Alzheimers Dis; 2008 Feb; 13(1):97-107. PubMed ID: 18334761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine for dementia in people with Down syndrome.
    Mohan M; Bennett C; Carpenter PK
    Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD007657. PubMed ID: 19160343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot double-blind treatment trial of memantine for alcohol dependence.
    Evans SM; Levin FR; Brooks DJ; Garawi F
    Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).
    Ferris S; Schneider L; Farmer M; Kay G; Crook T
    Int J Geriatr Psychiatry; 2007 May; 22(5):448-55. PubMed ID: 17117395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.
    Hanney M; Prasher V; Williams N; Jones EL; Aarsland D; Corbett A; Lawrence D; Yu LM; Tyrer S; Francis PT; Johnson T; Bullock R; Ballard C;
    Lancet; 2012 Feb; 379(9815):528-36. PubMed ID: 22236802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine.
    Jarvis B; Figgitt DP
    Drugs Aging; 2003; 20(6):465-76; discussion 477-8. PubMed ID: 12710865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
    Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
    Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.